Daclizumab

Interleukin-2 Receptor Blocking Antibody — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Daclizumab is a drug in the Interleukin-2 Receptor Blocking Antibody class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Interleukin 2 Receptor Antagonists and Interleukin 2 Receptor-directed Antibody Interactions. DrugCentral lists 1 molecular target, including IL2RA|IL2RB|IL2RG. Recorded indications include Relapsing remitting multiple sclerosis and Renal transplant rejection.

• Drug class: Interleukin-2 Receptor Blocking Antibody.
• Mechanism of action: Interleukin 2 Receptor Antagonists; Interleukin 2 Receptor-directed Antibody Interactions.
• Molecular targets: IL2RA|IL2RB|IL2RG (1 listed in DrugCentral).
• Indications: Relapsing remitting multiple sclerosis and Renal transplant rejection.
• ATC code: L04AC01 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Relapsing remitting multiple sclerosis
• Renal transplant rejection

Mechanism & targets

• Mechanism of action (MoA): Interleukin 2 Receptor Antagonists; Interleukin 2 Receptor-directed Antibody Interactions
• Established pharmacologic class: Interleukin-2 Receptor Blocking Antibody

Molecular targets (1)

Target	Gene	Action	Activity
Interleukin-2 receptor	IL2RA|IL2RB|IL2RG	other	Kd 8.00

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
1999-02-26	EMA	—	—
1997-12-10	FDA	—	HOFFMAN-LA ROCHE

ATC classification

ATC code	Therapeutic hierarchy
L04AC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Transplant dysfunction	2444.6
Ovarian cyst	1892.3
Transplant rejection	1784.1
Acne	1562.3
Alopecia	791.6
Multiple sclerosis relapse	471.8
Liver function test abnormal	426.4
Sleep disorder due to general medical condition, insomnia type	308.5
Rheumatoid arthritis	185.7
Kidney transplant rejection	132.6
Pneumonia	127.2
Loss of personal independence in daily activities	100.0

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 152923-56-3
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Daclizumab used for?

DrugCentral lists the following indications for Daclizumab: Relapsing remitting multiple sclerosis and Renal transplant rejection.

How does Daclizumab work?

Daclizumab is classified as Interleukin 2 Receptor Antagonists and Interleukin 2 Receptor-directed Antibody Interactions; its molecular targets in DrugCentral include IL2RA|IL2RB|IL2RG.

When was Daclizumab first approved?

Daclizumab was first approved by the FDA in 1997.

What drug class does Daclizumab belong to?

Daclizumab is in the Interleukin-2 Receptor Blocking Antibody class.

Sources

• DrugCentral drug card 4953 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201605 — compound record and bioactivity
• DrugBank DB00111 — drug record
• FDA UNII CUJ2MVI71Y — substance identity
• DailyMed: FDA labels for Daclizumab — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.